The OTCQB Venture Market offers early stage and developing companies the benefits of being publicly traded in the US and streamlined market standards which enable listed companies to provide a strong baseline of transparency to inform and engage with US investors.
To be eligible, companies must be current in their reporting, meet a minimum bid price test and undergo an annual verification and management certification process.
As a verified market with efficient access to US investors, OTCQB helps companies build shareholder value with a goal of enhancing liquidity and achieving fair valuation.
Artelo Biosciences is dedicated to the development and commercialization of proprietary endocannabinoid-modulating therapeutics designed to address significant unmet needs in multiple diseases and conditions, including cancer, pain, and inflammation.
CStone announces Phase I CS2009 data at ESMO 2025
Autonomix Medical secures new US patent to expand precision nerve-targeted therapies
Oxford BioDynamics and UEA develop 96% accurate blood test for Chronic Fatigue Syndrome
Merck completes acquisition of Verona Pharma to expand cardio-pulmonary portfolio
Celltrion launches AVTOZMA IV in the United States following FDA approval
Novartis to launch US direct-to-patient platform for Cosentyx
Vascarta completes VAS-101 osteoarthritis clinical trial
Sen-Jam Pharmaceutical and KVK Tech complete final development deliverables for SJP-002C
OSE Immunotherapeutics forms strategic alliance with Inserm Transfert and Nantes University